Trial Profile

MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; TPIV 200 (Primary)
Indications Adenocarcinoma; Carcinoma; Clear cell sarcoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms FRAPPE

Most Recent Events

11 Jun 2025 Status changed from suspended to recruiting.
21 Apr 2025 Status changed from recruiting to suspended due to lack of funding.
28 Sep 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com